A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma.
Phase 1
- Conditions
- Adenoid cystic carcinoma (ACC)MedDRA version: 21.0Level: PTClassification code: 10053231Term: Adenoid cystic carcinoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-508476-11-00
- Lead Sponsor
- Remix Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of REM-422 in targeting MYB mRNA in adenoid cystic carcinoma?
How does REM-422 compare to standard-of-care therapies like surgery and radiation in metastatic ACC?
What biomarkers, such as MYB expression levels, predict response to REM-422 in ACC patients?
What are the potential adverse events associated with REM-422 in ACC and how are they managed?
Are there other MYB-targeting mRNA degraders or combination therapies being developed by Remix Therapeutics for ACC?